VASCERN HTAD-WG Consensus statement on Fluoroquinolone use in HTAD.

The Heritable Thoracic Aortic Diseases Working Group (HTAD WG) has issued the following consensus statement on the use of fluoroquinolones in patients with Heritable Thoracic Aortic Diseases (HTAD): “In patients with HTAD, Fluoroquinolones should be used with caution because of a possible risk for exacerbation of aortic disease.  The use of alternatives … Continue reading VASCERN HTAD-WG Consensus statement on Fluoroquinolone use in HTAD.

Continue reading